Leukemia patients who enroll in LLS's PedAL screening trial and are found to have certain alterations will be directed to receive ziftomenib in a Phase I study.

The PedAL (Pediatric Acute Leukemia) Master Trial is at the heart of LLS's Dare to Dream Project to transform treatment and care for kids with blood cancer Infants and children with specific types ...

12, 2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

Pediatric patients with ALL experience, on average, about 15 different symptoms in their chemotherapy journey.

New markers of treatment resistance or toxicity are needed in pediatric acute lymphoblastic leukemia (ALL). Pharmacogenetic studies can be useful for childhood ALL because treatment protocols are ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases ...

University of Nebraska Medical Center, Omaha, NE.

The transcription factor (TF) TAL1 is a master regulator expressed at the early stages of normal thymocyte development. It is one of the major drivers in childhood T-lineage acute lymphoblastic ...